“云克”与^(153)Sm-EDTMP联合治疗恶性肿瘤骨转移的临床观察

The effect of combined Yunke and ^(153)Sm-EDTMP treatment in patients with skeletal metastases

目的分析"云克"与153Sm-EDTMP(乙二铵四甲撑膦酸)联合治疗恶性肿瘤骨转移的临床价值。方法125例骨转移癌患者,单纯"云克"治疗25例,单纯153Sm-EDTMP治疗76例,"云克"与153Sm-EDTMP联合治疗24例。结果联合治疗组91.7%(22/24)的患者骨痛消失或缓解,显著高于单纯153Sm-EDTMP治疗组(71.1%,54/76,P<0.05);联合治疗组骨转移灶治疗总有效率41.7%(10/24)显著高于单纯153Sm-EDTMP治疗组(15.8%,P<0.01)和单纯"云克"治疗组(0/25,P<0.01);联合治疗组骨痛"闪烁"现象发生率29.2%(7/24)显著低于单纯153Sm-EDTMP治疗组(69.7%,P<0.001)。结论"云克"与153Sm-EDTMP联合治疗骨转移癌疗效明显优于两者单独治疗,并可减少单纯153Sm-EDTMP治疗引起的骨痛"闪烁"现象发生率。

Objective To evaluate the effect of Yunke and ^153Sm - EDTMP treatment for painful skeletal metastases. Methods In total 125 patients with painful skeletal metastases, 25 cases were treated with Ynuke （Group A）, 19 cases were treated with ^153Sm -EDTMP （Group B）, 19 cases were treated with both ^153Sm -EDTMP and Ynuke （Group C）. Results 91. 7% of the patients were experienced pain relief after treatment Group C, significantly higher than those of Group B （71.1% ,P 〈 0.05 ） ; The size and amount of metastatic lesions decreased in 41.7% of patients after treatment in Group C, significantly higher than those of Group B （ 15.8% ,P 〈 0.01 ） and Group A （0/25, P 〈 0.01 ） ; Pain flare were observed in 29.2% of patients in Group C, which is significantly less than those of Group B （69.7%, P 〈 0.001 ）. Conclusion Combined treatment with Yunke and ^153 Sm - EDTMP were found more efficiently in patients with painful skeletal metastases than treatment with ^153 Sm - EDTMP or Yunke only, and may decrease the frequency of pain flare, which is significantly higher after treatment with ^153 Sm- EDTMP only.